Logo Image
Opinion|Videos|July 29, 2026

From Pipeline to Practice: Preparing for New Approvals and Navigating Maintenance Therapy Decisions in Myeloma

Clinicians brace for rapid multiple myeloma approvals, weighing patient-centered maintenance tradeoffs, long-term toxicity, costs, and emerging MRD-guided stopping decisions.

Episodes in this series

This episode, titled 'From Pipeline to Practice: Preparing for New Approvals and Navigating Maintenance Therapy Decisions in Myeloma,' features panelists discussing the following critical questions:

  1. Several significant approvals are anticipated in the multiple myeloma space over the next two years, including new agents, new formulations, and novel delivery methods (subQ). How are you preparing your practice for this wave of new options?
  2. Maintenance therapy continues to be an area of active discussion in terms of clinical benefit and cost. How are you currently approaching maintenance therapy for your patients?
  3. Do you feel the field has reached sufficient consensus on this question? What would be needed to reach a consensus?

Led by the moderator, the panelists examined how practices are preparing for a wave of anticipated approvals in the multiple myeloma space, including new agents, formulations, and subcutaneous delivery methods. The discussion reflected a pragmatic approach of waiting for full indication details before operationalizing new therapies, while ensuring that clinical teams are continuously educated and equipped to manage an increasingly complex and rapidly evolving treatment landscape. The panelists also explored how maintenance therapy is currently being approached in practice, noting that doublet maintenance with daratumumab and lenalidomide has become the standard for high-risk patients, while the long-term use of lenalidomide raises important questions about secondary malignancy risk and patient quality of life. The panelists further addressed whether the field has reached sufficient consensus on maintenance therapy decision-making, with agreement that the question remains very much in development.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Value-Based Care and Access Equity: How the Field Must Evolve to Keep Pace With Myeloma Innovation,' panelists will continue their discussion on multiple myeloma and highlight how value-based care frameworks, cost-effectiveness considerations, and access equity must evolve alongside the wave of therapeutic innovation in myeloma.